Literature DB >> 31695978

Single-best Choice Between Intermittent Versus Continuous Renal Replacement Therapy: A Review.

Nida Fathima1, Tooba Kashif2, Rajesh Naidu Janapala3, Joseph S Jayaraj3, Aisha Qaseem4.   

Abstract

Critically ill patients often develop multiorgan dysfunction syndrome. Acute kidney injury (AKI) is part of it. Renal replacement therapy (RRT) remains the primary choice of treatment in severely ill patients who develop AKI. Recent data have shown increased use of RRT in AKI patients. Therefore, the right choice of RRT plays an important role in the renal recovery of such patients. The question of which mode of RRT to apply has been the topic of study in the last two decades. Whether RRT should be conducted in intermittent mode, as intermittent hemodialysis (IHD), or in continuous mode, as continuous renal replacement therapy (CRRT), is still being investigated. CRRT has a hypothetical advantage when compared to IHD, as it involves a process in which there is gradual removal of fluids, better control of urea, better maintenance of the acid/base balance, and hemodynamic stability. However, IHD is more practical, cost-effective, does not require anticoagulation, decreases the bleeding risk, and removes the solute efficiently and rapidly in acute life-threatening conditions. Other modalities of RRT like sustained low-efficiency daily dialysis (SLEDD) and prolonged intermittent renal replacement therapy (PIRRT) have shown to encompass the benefits of both CRRT in terms of hemodynamic stability and IHD in terms of cost-efficiency. Although SLEDD is progressively being used as an alternative to CRRT and IHD, very few studies have shown to support it. In this article, we try to summarize the advantages and disadvantages of the different techniques used in RRT. With SLEDD gaining more popularity among the different modalities of RRT, we want to assess the possibility of its routine implementation as the single-best choice for RRT.
Copyright © 2019, Fathima et al.

Entities:  

Keywords:  acute kidney injury; continuous renal replacement therapy; effectiveness; intermittent hemodialysis; renal failure; renal recovery; renal replacement therapy

Year:  2019        PMID: 31695978      PMCID: PMC6820322          DOI: 10.7759/cureus.5558

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  24 in total

1.  Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial.

Authors:  Christophe Vinsonneau; Christophe Camus; Alain Combes; Marie Alyette Costa de Beauregard; Kada Klouche; Thierry Boulain; Jean-Louis Pallot; Jean-Daniel Chiche; Pierre Taupin; Paul Landais; Jean-François Dhainaut
Journal:  Lancet       Date:  2006-07-29       Impact factor: 79.321

2.  Efficacy and hemodynamic outcome of prolonged intermittent renal replacement therapy (PIRRT) in critically ill patients: a preliminary report.

Authors:  Ranistha Ratanarat; Thunyarat Chaipruckmalakarn; Nopparat Laowahutanont; Nuttasith Larpparisuth; Somkiat Vasuvattakul
Journal:  J Med Assoc Thai       Date:  2012-02

Review 3.  Effects of renal replacement therapy on renal recovery after acute kidney injury.

Authors:  Antoine G Schneider; Sean M Bagshaw
Journal:  Nephron Clin Pract       Date:  2014-09-24

Review 4.  Acute renal failure.

Authors:  Norbert Lameire; Wim Van Biesen; Raymond Vanholder
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

5.  A randomized controlled trial comparing intermittent with continuous dialysis in patients with ARF.

Authors:  Joshua J Augustine; Diane Sandy; Tracy H Seifert; Emil P Paganini
Journal:  Am J Kidney Dis       Date:  2004-12       Impact factor: 8.860

6.  Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure.

Authors:  A Davenport; E J Will; A M Davidson
Journal:  Crit Care Med       Date:  1993-03       Impact factor: 7.598

7.  Continuous arteriovenous haemofiltration. A new kidney replacement therapy.

Authors:  P Kramer; J Schrader; W Bohnsack; G Grieben; H J Gröne; F Scheler
Journal:  Proc Eur Dial Transplant Assoc       Date:  1981

Review 8.  Renal replacement therapy in the ICU: intermittent hemodialysis, sustained low-efficiency dialysis or continuous renal replacement therapy?

Authors:  Amanda Ying Wang; Rinaldo Bellomo
Journal:  Curr Opin Crit Care       Date:  2018-12       Impact factor: 3.687

9.  Effect of hemorrhagic reduction in blood pressure on recovery from acute renal failure.

Authors:  S P Kelleher; J B Robinette; F Miller; J D Conger
Journal:  Kidney Int       Date:  1987-03       Impact factor: 10.612

Review 10.  Pro/con debate: continuous versus intermittent dialysis for acute kidney injury: a never-ending story yet approaching the finish?

Authors:  Raymond Vanholder; Wim Van Biesen; Eric Hoste; Norbert Lameire
Journal:  Crit Care       Date:  2011-01-28       Impact factor: 9.097

View more
  4 in total

1.  Meeting the Demand for Renal Replacement Therapy during the COVID-19 Pandemic: A Manufacturer's Perspective.

Authors:  Michael S Anger; Claudy Mullon; Linda H Ficociello; David Thompson; Michael A Kraus; Pete Newcomb; Robert J Kossmann
Journal:  Kidney360       Date:  2020-12-29

2.  Comparison of the Treatment Efficacy of Continuous Renal Replacement Therapy and Intermittent Hemodialysis in Patients With Acute Kidney İnjury Admitted to the Intensive Care Unit.

Authors:  Fatma Yılmaz Aydın; Emre Aydın; Ali Kemal Kadiroglu
Journal:  Cureus       Date:  2022-01-29

3.  Continuous Renal Replacement Therapy for Hypertension Complicated by Refractory Heart Failure: An Analysis of Safety and Nursing Highlights.

Authors:  Miaoli Zhang; Jingfeng Li
Journal:  Comput Math Methods Med       Date:  2022-09-14       Impact factor: 2.809

Review 4.  Renal replacement therapy in cancer patients with acute kidney injury (Review).

Authors:  Mircea Lupuşoru; Gabriela Lupuşoru; Ioana Ailincăi; Georgiana Frățilă; Andreea Andronesi; Elena Micu; Mihaela Banu; Radu Costea; Gener Ismail
Journal:  Exp Ther Med       Date:  2021-06-11       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.